O1 Activity of the FGFR1–3 inhibitor infigratinib in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder: Latest efficacy findings and comprehensive genomic profiling/cell-free DNA data
De Giorgi U, Pal S, Rosenberg J, Hoffman-Censits J, Quinn D, Petrylak D, Galsky M, Vaishampayan U, Gupta S, Burris H, Soifer H, Li G, Dambkowski C, Moran S, Ye Y, Daneshmand S, Delord J, Bajorin D. O1 Activity of the FGFR1–3 inhibitor infigratinib in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder: Latest efficacy findings and comprehensive genomic profiling/cell-free DNA data. European Urology Open Science 2019, 18: e3405-e3406. DOI: 10.1016/s1569-9056(19)34582-8.Peer-Reviewed Original ResearchInfigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.
Dizman N, Rosenberg J, Hoffman-Censits J, Quinn D, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Soifer H, Li G, Dambkowski C, Moran S, Ye Y, Daneshmand S, Bajorin D, Pal S. Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results. Journal Of Clinical Oncology 2019, 37: 4510-4510. DOI: 10.1200/jco.2019.37.15_suppl.4510.Peer-Reviewed Original ResearchUpper tract UCMetastatic urothelial carcinomaUrothelial carcinomaPrior platinum-based chemotherapyUpper tract urothelial carcinomaDisease control ratePrior antineoplastic therapyPlatinum-based chemotherapyOverall response rateComprehensive genomic profilingDistinct biologic characteristicsFGFR3-TACC3 fusionMutations/fusionsCell-free DNA resultsGood responseEligible ptsS249C mutationAdjuvant studiesFGFR3 alterationsControl rateAntineoplastic therapyDistinct biologyBiologic characteristicsResponse rateInfigratinib